|By PR Newswire||
|March 31, 2014 08:00 PM EDT||
DUBLIN, April 1, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/5wxkx8/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering.
The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.
Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts.
There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled.
Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market.
The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow.
Key Topics Covered:
1. Introduction to RNA Interference (RNAi) Therapy
2. Benefits of RNA Interference (RNAi) Therapy
3. RNA Interference (RNAi) Drug Delivery Mechanics
4. Global RNA Interference (RNAi) Therapy Market Overview
5. Global RNA Interference (RNAi) Market Dynamics
6. RNAi Clinical Pipeline by Phase, Indication & Country
7. Suspended & Discontinued RNAi Profiles
8. Competitive Landscape
- Arrowhead Research
- Alnylam Pharmaceuticals
- Benitec Biopharma
- Dicerna Pharmaceuticals
- InteRNA Technologies
- Isis Pharmaceuticals
- RXi Pharmaceuticals
- Santaris Pharma
- Silence Therapeutics
- Tekmira Pharmaceuticals Corporation
For more information visit http://www.researchandmarkets.com/research/5wxkx8/global_rna
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Dec. 9, 2016 11:30 PM EST Reads: 1,145
Dec. 9, 2016 10:45 PM EST Reads: 513
Dec. 9, 2016 10:30 PM EST Reads: 1,715
Dec. 9, 2016 10:00 PM EST Reads: 299
Dec. 9, 2016 09:45 PM EST Reads: 2,006
Dec. 9, 2016 09:30 PM EST Reads: 1,282
Dec. 9, 2016 08:00 PM EST Reads: 1,023
Dec. 9, 2016 07:45 PM EST Reads: 725
Dec. 9, 2016 06:45 PM EST Reads: 5,148
Dec. 9, 2016 06:15 PM EST Reads: 1,767
Dec. 9, 2016 05:30 PM EST Reads: 2,375
Dec. 9, 2016 05:15 PM EST Reads: 1,891
Dec. 9, 2016 05:15 PM EST Reads: 1,472
Dec. 9, 2016 05:15 PM EST Reads: 422
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
Dec. 9, 2016 05:00 PM EST Reads: 2,079